Remedium Capital Partners, LLC
Position in SYRE — Spyre Therapeutics, Inc.
CIK 2104501
FORT LAUDERDALE, FL
Position in SYRE
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$129,988,923
+$56,536,632 QoQ
Shares Held
1,464,169
+0.5% QoQ
Ownership
1.66%
of shares outstanding
% of Portfolio
28.78%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Remedium Capital Partners, LLC holds $451,627,233 across 6 Biotechnology names. SYRE ranks #2 (28.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ORKA |
Oruka Therapeutics, Inc.
|
1,565,661 | $149,003,957 | |
| 2 | SYRE |
Spyre Therapeutics, Inc.
This page
|
1,464,169 | $129,988,923 | |
| 3 | 586,691 | $77,871,496 | |||
| 4 | DMRA |
Damora Therapeutics, Inc.
|
2,045,473 | $53,202,752 | |
| 5 | JBIO |
Jade Biosciences, Inc.
|
1,577,750 | $35,057,605 | |
| 6 | CBIO |
Crescent Biopharma, Inc.
|
361,250 | $6,502,500 |
All Filings in SYRE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $129,988,923 | 1,464,169 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $73,452,291 | 1,456,231 | Shares | Sole | 2026-05-19 | |
| 2025-12-31 | $47,706,127 | 1,456,231 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||